Compare DexCom, Inc. (DXCM) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kyndryl Holdings Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Kyndryl Holdings Inc trades at $11.86 (market cap $2.49B). The key difference: DexCom, Inc. is far larger — about 12.8× Kyndryl Holdings Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Kyndryl Holdings Inc for 36 Days on average.
| DXCM | KD | |
|---|---|---|
Market Cap | $31.81B | $2.49B |
Volume | 2,861,821 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $92.34 | $29.76 |
52-Week Low | $54.84 | $10.59 |
Typical Hold Time | 62 Days | 36 Days |
Enterprise Value | $31.26B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Kyndryl Holdings (KD) trades at $11.45, down 0.26% on the day, with technical indicators showing bearish momentum. The company reported mixed quarterly results, missing Q4 2025 and Q1 2026 EPS estimates but beating in Q2 2026. Recent financials show improved profitability with 2025 net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B in 2025. Analyst sentiment is cautious with a consensus 'Hold' rating and $14.67 price target, while institutional activity includes recent purchases by Virginia Retirement Systems.
KD presents a turnaround story with improving profitability but faces revenue headwinds and competitive pressures. The stock trades at reasonable valuation multiples (P/E 30.95, P/S 0.18) with positive cash flow generation. Key risks include ongoing revenue declines and high debt levels, while opportunities exist in AI initiatives and government contracts. The current technical weakness may present entry points for patient investors betting on management's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
